Takumi KONDO

Dr. Takumi KONDO

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
TUTomohiro Urata
Tomohiro Urata
YNYusuke Naoi
Yusuke Naoi
AJAixiang Jiang
Aixiang Jiang
MBMerrill Boyle
Merrill Boyle
KSKazutaka Sunami
Kazutaka Sunami
DEDaisuke Ennishi
Daisuke Ennishi
The distribution and clinical impact of cell-of-origin (COO) subtypes of diffuse large B-cell lymphoma (DLBCL) outside Western countries remain unknown. Recent literature also suggests that there is an additional COO subtype associated with the germinal center dark zone (DZ) that warrants wider validation to generalize clinical relevance. Here, we assembled a cohort of Japanese patients with untreated DLBCL and determined the refined COO subtypes, which include the DZ signature (DZsig), using the NanoString DLBCL90 assay. To compare the distribution and clinical characteristics of the molecular subtypes, we used a data set from the cohort of British Columbia Cancer (BCC) (n = 804). Through the 1050 patient samples on which DLBCL90 assay was successfully performed in our cohort, 35%, 45%, and 6% of patients were identified to have germinal center B-cell–like (GCB) DLBCL, activated B-cell–like (ABC) DLBCL, and DZsig-positive (DZsigpos) DLBCL, respectively, with the highest prevalence of ABC-DLBCL, differing significantly from the BCC result (P < .001). GCB-DLBCL, ABC-DLBCL, and DZsigpos-DLBCL were associated with 2-year overall survival rates of 88%, 75%, and 66%, respectively (P < .0001), with patients with DZsigpos-DLBCL having the poorest prognosis. In contrast, GCB-DLBCL without DZsig showed excellent outcomes after rituximab-containing immunochemotherapy. DZsigpos-DLBCL was associated with the significant enrichment of tumors with CD10 expression, concurrent MYC/BCL2 expression, and depletion of microenvironmental components (all, P < .05). These results provide evidence of the distinct distribution of clinically relevant molecular subtypes in Japanese DLBCL and that refined COO, as measured by the DLBCL90 assay, is a robust prognostic biomarker that is consistent across geographical areas.

1 March 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
TTToshiki Terao
Toshiki Terao
KMKen-ichi Matsuoka
Ken-ichi Matsuoka
HUHiroko Ueda
Hiroko Ueda
AMAkifumi Matsumura
Akifumi Matsumura
CMChisato Matsubara
Chisato Matsubara
YMYoshinobu Maeda
Yoshinobu Maeda
Mutations in the fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) and tyrosine kinase domain (TKD) are common in acute myeloid leukemia (AML)

24 March 2022 in Transfusion
Verified
Journal Article
Closed access
TKTakumi KONDO
Takumi KONDO
NFNobuharu Fujii
Nobuharu Fujii
KFKeiko Fujii
Keiko Fujii
YSYuichi Sumii
Yuichi Sumii
TUTomohiro Urata
Tomohiro Urata
YMYoshinobu Maeda
Yoshinobu Maeda

24 April 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
YSYuichi Sumii
Yuichi Sumii
TKTakumi KONDO
Takumi KONDO
SIShuntaro Ikegawa
Shuntaro Ikegawa
TFTakuya Fukumi
Takuya Fukumi
MIMiki Iwamoto
Miki Iwamoto
KMKen-ichi Matsuoka
Ken-ichi Matsuoka
Posttransplant cyclophosphamide (PTCy) is associated with a low incidence of chronic graft-versus-host disease (cGVHD) following hematopoietic stem cell (HSC) transplantation. Previous studies have shown the important roles of B cell immunity in cGVHD development. Here, we investigated the long-term reconstitution of B lymphopoiesis after PTCy using murine models. We first demonstrated that the immune homeostatic abnormality leading to cGVHD is characterized by an initial increase in effector T cells in the bone marrow and subsequent B and Treg cytopenia. PTCy, but not cyclosporine A or rapamycin, inhibits the initial alloreactive T cell response, which restores intra-bone marrow B lymphogenesis with a concomitant vigorous increase in Tregs. This leads to profound changes in posttransplant B cell homeostasis, including decreased B cell activating factors, increased transitional and regulatory B cells, and decreased germinal center B cells. To identify the cells responsible for PTCy-induced B cell tolerance, we selectively depleted Treg populations that were graft or HSC derived using DEREG mice. Deletion of either Treg population without PTCy resulted in critical B cytopenia. PTCy rescued B lymphopoiesis from graft-derived Treg deletion. In contrast, the negative effect of HSC-derived Treg deletion could not be overcome by PTCy, indicating that HSC-derived Tregs are essential for maintaining favorable B lymphopoiesis following PTCy. These findings define the mechanisms by which PTCy restores homeostasis of the B cell lineage and reestablishes immune tolerance.

20 December 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
AYAkira Yamamoto
Akira Yamamoto
NFNobuharu Fujii
Nobuharu Fujii
KSKeisuke Seike
Keisuke Seike
SSSeiichiro Sugimoto
Seiichiro Sugimoto
YNYusuke Naoi
Yusuke Naoi
YMYoshinobu Maeda
Yoshinobu Maeda
Bronchiolitis obliterans (BO) is a severe, fibrotic manifestation of chronic graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Macrophage-derived TGF-β is linked to GVHD-related fibrosis; however, its role in BO remains unclear. Given emerging evidence of macrophage-to-myofibroblast transition (MMT) in fibrosis, this study aimed to investigate whether MMT contributes to BO development. We analyzed lung samples from three HSCT recipients with BO who underwent lung transplantation, with tissues from two patients with lung cancer as controls. Immunofluorescent staining for CD68, CD206, and α-SMA was used to identify cells undergoing MMT. Spatial transcriptomics was performed to profile gene expression in foamy macrophages across anatomical regions and histological stages, compared to control peribronchiolar regions. Immunostaining showed strong co-expression of CD68, CD206, and α-SMA in foamy macrophages within and surrounding bronchioles in BO samples, with minimal expression in controls, suggesting MMT involvement. In BO, spatial transcriptomics revealed upregulation of macrophage- and TGF-β signaling genes, with distinct stage- and region-specific gene expression patterns. Unsupervised clustering revealed a shift from inflammation to fibrosis. These findings indicate that MMT contributes to fibrosis in BO. Gene expression shifts from inflammation to fibrosis as the disease advances, underscoring the importance of early intervention.